title: Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies.
authors.affiliation: Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. breccia@bce.uniroma1.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Loglisci
authors.forename: Adriano
authors.initials: A
authors.lastname: Salaroli
authors.forename: Alessandra
authors.initials: A
authors.lastname: Serrao
authors.forename: Luigi
authors.initials: L
authors.lastname: Petrucci
authors.forename: Irene
authors.initials: I
authors.lastname: Zacheo
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000964:Antimetabolites, Antineoplastic; D006397:Hematinics; D001374:Azacitidine